This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the NIH's Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $751,043 research project at the University of Massachusetts Medical School focused on investigating the cellular and molecular mechanisms underlying the complex co-morbidity of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The project will leverage single-cell sequencing technologies and other...
The National Institute on Drug Abuse (NIDA) awarded a $558,085 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the University of California, Irvine (UCI) to support an interdisciplinary research initiative titled "DMFV-SCORCH Project". This 5-year project aims to uncover multi-scale dysregulations resulting from HIV and opioid use disorder (OUD) through population-scale single-nuclei sequencing data analysis and functional validations using advanced genomic...
This Project Grant award of $2,312,085, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the molecular mechanisms linking HIV infection and opioid use disorder that contribute to neuroinflammation and HIV-associated neurocognitive disorders (HAND). The research, led by the Trustees of Boston University's Medical Campus, will utilize primary human iPSC-derived microglia cultures to...
This Project Grant award of $558,668 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to elucidate the shared and distinct molecular mechanisms underlying the interplay between HIV, substance use disorders (SUD), and neuropsychiatric/neurodegenerative conditions. The award to Massachusetts Institute of Technology (MIT) aims to leverage single-cell transcriptomic, epigenomic, and spatial datasets along with...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will provide $234,000.00 to Georgetown University to conduct research on the effect of opioids on HIV transcription and latency. The key objectives are to understand the mechanisms by which opioids such as fentanyl, morphine, and methadone influence HIV proviral transcription in microglia and astrocytes, as well as to longitudinally measure and...
The National Institute on Drug Abuse (NIDA) awarded a $687,416 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The grant supports research to develop therapeutically effective latency-promoting agents (LPAs) that can "block" HIV reactivation and "lock" HIV in a silenced state, even in the presence of addictive substances, for people living...
This $284,040 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to conduct integrated single-cell and spatial mapping of the habenula circuitry to identify projection-specific molecular pathways associated with opioid exposure. The Lieber Institute for Brain Development in Baltimore, MD will lead this research effort from September 1, 2024 to August 31, 2026. The project will generate a...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a research study focused on understanding the impact of the opioid fentanyl on individuals with HIV. The total funding amount is $587,188, with the award period running from July 15, 2025 to March 31, 2030. The key products and services to be delivered under this grant include: A multi-omics approach and complementary in vivo and ex vivo studies to...
This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $569,743 to Yale University to conduct the "Y-SCORCH 2.0" research project. The goal is to further analyze transcriptomic and epigenetic data from the SCORCH consortium to identify potential treatment targets for the intersection of opioid use disorder (OUD) and HIV, which together affect over 20 million individuals globally. The key products and services...